An IND for InterveXion’s chimeric anti-METH monoclonal antibody, ch-mAb7F9, was submitted to FDA in March and became active in early April. Plans for the Phase 1a clinical study in healthy volunteers are being finalized and we expect to begin screening potential subjects in mid-April. This study will be conducted by the Quintiles Phase 1 Unit in Overland Park, KS.